Survey 2022 insights
Migraine in Aotearoa New Zealand 2022 Survey
Aim of the survey
The aim of the survey was to collect data on:
- chronic migraine
- medication overuse
- types of acute and preventive medications used
- non-medication acute and preventive treatments used
- disability from migraine
- impact of migraine on work
- use of, access to and experience of health services
- experiences of stigma
- what could be improved for people with migraine.
Survey development and data collection
The survey was developed using existing questions, specifically the Migraine Identification test (ID-Migraine testTM), the Migraine Disability Assessment Scale (MIDAS), demographic questions used by Stats NZ and the Ministry of Health and qualitative (open-ended) questions. The survey questionnaire is available below.
The survey was available online from 22 August 2022 to 7 Oct 2022 via a link on the MFANZ website landing page. It was promoted through our social media channels and networks, including Health Navigator, Neurological Foundation, New Zealand Pain Society, and a large engineering firm through a staff newsletter.
Media articles linking to the survey webpage included a primary care electronic newsletter, an article by an AUT journalist and a press release on Scoop. For more information about the survey, see our methodology report.
Key insight reports
We have published 23 key insight reports from the survey. To date, we’ve used the survey results as a New Zealand evidence-base in our Emgality application to Pharmac, have published a paper on the impact of migraine, and have had a 4th year medical student analyse results on access to health care for publication.
